Quarterly ResultAug 3, 2026, 05:22 PM
ClearPoint Neuro Q2 Revenue +18%; Net Loss $(11.3)M
AI Summary
ClearPoint Neuro reported an 18% increase in total revenue to $10.88 million for the second quarter of 2026, and a 30% increase to $23.01 million for the first six months. Despite strong revenue growth, the company's net loss significantly widened to $(11.34) million for the quarter and $(20.89) million for the six-month period, primarily due to increased operating expenses. Cash and cash equivalents decreased to $29.36 million from $45.92 million at year-end 2025, with net cash used in operating activities rising to $(14.98) million for the six months.
Key Highlights
- Q2 2026 total revenue increased 18% to $10.88 million.
- H1 2026 total revenue increased 30% to $23.01 million.
- Q2 2026 net loss widened to $(11.34) million from $(5.84) million YoY.
- H1 2026 net loss widened to $(20.89) million from $(11.86) million YoY.
- Cash and cash equivalents decreased to $29.36 million from $45.92 million.
- Net cash used in operating activities was $(14.98) million for H1 2026.
- Acquisition of IRRAS in 2025 expanded portfolio into neurocritical care.
- Cumulative deficit reached $237.8 million as of June 30, 2026.
Price Impact
More from CLPT